Somatic Gene Therapy, Paradigm Shift or Pandora's Box: A Perspective on Gene Therapy; M. Lawler. Gene Therapy for Cancer: Deceiving the Malignant Cell; M. Lawler. Gene Self-Assembly (GENSA): Facilitating the Construction of Genes and Vectors; C.P. Hodgson. Gene Expression; J. Kaur, et al. Tumour Genotype and Response to Cytotoxic Gene Therapy; P.T. Daniel, et al. Protein Binding Matrices: Tools for Phenol-free Cloning and Vector Assembling; V.I. Evtushenko. Gene Transfer into Eukaryotic Cells; M. Weber. Plasmid DNA Manufacturing; M. Schleef, et al. Quality Assurance and Quality Control for Viral Therapeutics; S.S. Kuwahara. Analytical Assays to Characterise Adenoviral Vectors and Their Applications; E. Lehmberg, et al. Validation of Gene Therapy Manufacturing Processes: A Case Study for Adenovirus Vectors; D. Vacante, et al. Gene Delivery; A. Anand. Regulatory Issues in Gene Therapy. Good Science - Good Sense; N. Chew, J.A. Cavagnaro. Regulatory Aspects in Gene Therapy: Special Highlights on European Regulation; O. Cohen-Haguenhauer. Regulatory Issues for Process Development and Manufacture of Plasmids Under Contract; J.M. Jenco. Risk Assessment in Gene Therapy; A. Anand, S.K. Arora. Index.
Advances in molecular biology and recombinant DNA technology have accelerated progress in many fields of life science research, including gene therapy. A large number of genetic engineering approaches and methods are readily available for gene cloning and therapeutic vector construction. Significant progress is being made in genomic, DNA sequencing, gene expression, gene delivery and cloning. Thus gene therapy has already shown that it holds great promise for the treatment of many diseases and disorders. In general it involves the delivery of recombinant genes or transgenes into somatic cells to replace proteins with a genetic defect or to transfer with the pathological process of an illness. The viral and non-viral delivery systems may hold the potential for future non-invasive, cost-effective oral therapy of genetically-based disorders.
Recent years have seen considerable progress in the discovery and early clinical development of a variety of gene therapeutic products. The availability, validation, and implementation of gene therapeutic products has also enabled success in testing and evaluation. New challenges will need to be overcome to ensure that products will also be successful in later clinical development and ultimately for marketing authorisation. These new challenges will include improvements in delivery systems, better control of in-vivo targeting, increased level transduction and duration of expression of the gene, and manufacturing process efficiencies that enable reduction in production costs. Perhaps profound understanding of regulated gene design may result in innovative bioproducts exhibiting safety and efficacy profiles that are significantly superior to those achieved by the use of naturally occurring genes. This procedure may contribute considerably to fulfilling standards set by regulatory authorities.
This book provides an overview of the current advances in the field of gene therapy
Springer Book Archives